| Hazard Information | Back Directory | [Uses]
Narnatumab (IMC-RON8) is a neutralizing human monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), with a Kd of 32 pM. Narnatumab can be used for the research of cancer[1]. | [in vivo]
Narnatumab (2-60 mg/kg; i.p. every 3 days) shows antitumor activity in non-small cell lung cancer (NSCLC) and bladder cancer models in athymic mice[1].
Narnatumab exhibits terminal half-life (t1/2=5.2 d) and achieves antitumor effects at a steady-state plasma trough level of approximately 140 μg/mL in mice[1]. | Animal Model: | Female athymic nu/nu mice (6-8 weeks) were injected NCI-H292 and BFTC-905 cells[1] | | Dosage: | 2, 20, 60 mg/kg | | Administration: | I.p. every 3 days for 36 and 18 days | | Result: | Inhibited tumor growth in a dose-dependent manner.
|
| [References]
[1] LoRusso PM, et, al. Phase 1 study of narnatumab, an anti-RON receptor monoclonal antibody, in patients with advanced solid tumors. Invest New Drugs. 2017 Aug;35(4):442-450. DOI:10.1007/s10637-016-0413-0 |
|
| Company Name: |
Biolab Reagents
|
| Tel: |
18108604356 18108604356 |
| Website: |
www.biolabreagent.com/ |
| Company Name: |
Cell Sciences
|
| Tel: |
9785721070 |
| Website: |
www.cellsciences.com |
|